Comparative Pharmacology
Head-to-head clinical analysis: MYCHEL versus SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYCHEL versus SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH.
MYCHEL vs SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mychel is a topical antifungal agent that inhibits ergosterol synthesis by binding to fungal cytochrome P450 14α-demethylase, disrupting fungal cell membrane integrity.
Sulfamethoxazole inhibits bacterial dihydropteroate synthase, blocking folic acid synthesis. Trimethoprim inhibits bacterial dihydrofolate reductase, blocking reduction of dihydrofolate to tetrahydrofolate. Sequential blockade produces bactericidal effect.
Adults: 200 mg orally twice daily for 14 days.
One double-strength tablet (160 mg trimethoprim/800 mg sulfamethoxazole) orally every 12 hours.
None Documented
None Documented
Terminal half-life: 8.5-12 hours (mean 10.2 h) in normal renal function; prolonged to 18-30 h in severe renal impairment (CrCl <30 mL/min)
Sulfamethoxazole: 9-11 hours; trimethoprim: 8-11 hours. In severe renal impairment (CrCl <15 mL/min), half-life prolongs significantly (up to 30 hours for trimethoprim).
Renal: ~70% unchanged; fecal: ~15% as metabolites; biliary: ~10%
Both sulfamethoxazole and trimethoprim are primarily excreted via the kidneys. Sulfamethoxazole: ~30% as unchanged drug, ~50% as N4-acetyl metabolite; trimethoprim: ~80% as unchanged drug. Fecal elimination is minimal (<5%).
Category C
Category D/X
Antibiotic
Antibiotic